Melanoma and immunotherapy bridge 2015

MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh

Background: Approximately 50 % of melanoma patients present activating mutations in the BRAF oncogene. For these patients new therapeutic options have been made available in recent years represented by BRAF and MEK kinase inhibitors (KIs). However, the main issue remains the development of drug resistance, which is responsible for disease relapse within months after treatment. Established drug resistance is caused in most cases by several gene mutations which either reactivate the MAPK/ ERK pathway or involve activation of receptor tyrosine kinase driven survival pathways. However, besides mutational events it is emerging that a wealth of adaptive changes take place in melanoma cells after drug exposure which heavily contribute to the development of resistance. Our group has focused its attention over the past years to some of these adaptive changes in the search of new therapeutic targets. Materials and methods: Up to ten melanoma cell lines bearing different mutations in the BRAF gene were exposed to BRAFi and/or MEKi from 2 to 72 h and harvested for protein and RNA extraction. Drug resistant melanoma cell populations were selected using increasing drug concentrations over a 2 months period. Activation of RTKs and intracellular signaling was assesses by RTK arrays and western blotting. ErbB3 receptor was inhibited by monoclonal antibodies A3 and A4. Changes in miRNA levels were detected by Nanostring technology or by RT-PCR. Tumor biopsies were obtained from patients before KI therapy or after relapse and used for RNA extraction. Results: We first showed that ErbB3 is the main receptor to be phosphorylated after short term exposure to KIs in different melanoma lines. ErbB3 activation and in turn AKT phosphorylation depends on an autocrine loop due to increased neuregulin-1 production. Anti-ErbB3 mAbs cause receptor internalization and degradation and potentiate the growth inhibitory effect of BRAFi and MEKi in vitro and in vivo. Most importantly mAbs-induced ErbB3 inhibition impairs the development of resistance in vitro and tumor relapse in vivo after therapy discontinuation. More recently we focused our attention on microRNA deregulations after drug exposure of melanoma cells. Our preliminary data show the involvement of a network of miRNAs on the modulation of the response to KIs.

Journal of Translational Medicine
It is generally assumed that in order to be used as targets of antibodybased immunotherapy of malignant diseases, tumor antigens have to be expressed on the plasma membrane of tumor cells. This assumption has markedly reduced the number of tumor antigens which can be targeted with antibody-based immunotherapy, since only a few of the molecules expressed on the plasma membrane of tumor cells meet the criteria required to be used as targets of antibody-based immunotherapy. Intracellular TAs which analyses with T cells have shown to be much more diverse than those expressed on plasma membrane, have been excluded from studies to identify targets of antibody-based immunotherapy for the treatment of malignant diseases. We have hypothesized that, under certain experimental conditions and especially in malignant cells, intracellular molecules may migrate to cell surface and become accessible to interact with the corresponding antibodies. Our hypothesis is supported by the isolation of the human monoclonal antibody (mAb) W9, which recognizes an extracellular epitope of the intracellular chaperone molecule glucose regulated protein of 94,000 Da (Grp94). The mAb W9 defined Grp94 epitope is expressed on various types of malignant cells including melanoma. In several types of cancer, the mAb W9 defined Grp94 epitope is expressed not only on differentiated cancer cells, but also on cancer initiating cells (CICs). The mAb W9 defined Grp94 epitope is upregulated on BRAF V600E melanoma cells by incubation with BRAF inhibitor, and with chemotherapeutic agents. In contrast, the mAb W9 defined Grp94 epitope is not detectable on normal cells. Therefore it represents an attractive target to implement antibody-based immunotherapy of various types of solid tumors. In this study we have investigated the in vitro and in vivo anti-tumor activity of mAb W9 utilizing malignant melanoma as a model. The results obtained indicate that mAb W9 inhibits the growth of melanoma cells. This effect reflects the induction of apoptosis as well as the inhibition of several signaling pathways including Erk, Akt and FAK pathways. The anti-tumor activity of mAb W9 is enhanced by the small molecule LDE225, an inhibitor of SHH pathway. Furthermore, mAb W9 delays the development of BRAF inhibitor resistance in melanoma cells with mutant BRAF. Lastly, mAb W9 induces the regression of experimental lung metastasis established in immunodeficient mice by intravenous injection of melanoma M21 cells. If representative of a general phenomenon, these results suggest that intracellular tumor antigens may be a useful source of targets for antibody-based immunotherapy of melanoma and other types of solid tumors. J Transl Med 2016, 14(Suppl 1):S65 responsive ones by breaking down the barriers to immune cell infiltration and promoting development of anti-tumor T cells [3][4][5]. These proimmunogenic effects of radiation are modulated by the pre-existing tumor microenvironment, and are dependent on the dose and fractionation of radiation employed [6,7]. Immunogenic cell death is induced by radiation in a dose-dependent way, with higher ablative single doses being more effective in vitro [8]. However, in vivo the pro-immunogenic effects of radiation are countered by generation of immunosuppressive mediators. We have recently identified a critical role of transforming growth factor beta (TGFβ) in regulating development of anti-tumor T cells and tumor rejection following radiotherapy [9]. We are currently investigating the role of other TGFβ family members, as well as adenosinergic pathways in regulating the shift between immune activation and immune suppression in the tumor following radiotherapy. The overarching goal of our work is to define radiation interactions with the microenvironment of a given tumor, and devise a personalized approach to optimize in situ vaccination by radiation. Results of these studies will improve the design of clinical trials testing radiation in combination with immune checkpoint inhibitors and other immunotherapies. J Transl Med 2016, 14(Suppl 1):S65 Immune checkpoint blockade with agents such as ipilimumab, pembrolizumab, and nivolumab has dramatically changed the outlook for patients with metastatic melanoma. Several studies have investigated the combination of various checkpoint blocking antibodies such as the combination of ipilimumab and nivolumab and the combination of ipilimumab and pembrolizumab. We await overall survival data from phase III studies to determine the true values of combining immune checkpoint inhibitors. Nonetheless, combinations have demonstrated impressive objective response rates and progression free survival. In this talk, we will discuss the available data for combining immune checkpoint inhibitors, side effects, and future directions.
Background: Multiple mechanisms of melanoma-induced immune escape contribute to the failure of the spontaneous or vaccineinduced immune T cell responses to promote tumor regression in humans. In particular, a number of inhibitory pathways play a critical role in impeding T cell responses to tumor antigens, including PD-1, Tim-3 and TIGIT. Results: Our findings show that PD-1, Tim-3 and TIGIT are upregulated by CD8 + and CD4 + T cells at the periphery and at tumor sites in patients with metastatic melanoma. We observed that melanoma cells and antigen presenting cells in metastatic melanoma express the PD-1, Tim-3 and TIGIT inhibitory ligands. Dual PD-1/Tim-3 and dual PD-1/TIGIT blockades enhanced the expansion and function of TAspecific CD8 + T cells isolated from patients with advanced melanoma. Interestingly, CD8 + TILs downregulated CD226, the costimulatory counterpart to TIGIT, supporting an imbalance of TIGIT/CD226 expression in metastatic melanoma, which may contribute to melanomainduced T cell dysfunction. Conclusion: Collectively, our findings present the rationale for targeting multiple inhibitory pathways including PD-1, Tim-3 and TIGIT to better counteract melanoma-induced cell dysfunction and improve melanoma patients 'clinical outcome. T cells engineered to express high affinity T cell receptors or chimeric antigen receptors (CAR) have been successful for treating cancer and hematological malignancies. We are using anti-CD19 and anti-CD22 CAR T cells to treat patients with acute lymphocytic leukemia and B cell lymphomas. While early phase clinical studies with these therapies have been promising, occasionally, the CAR T cells fail to expand in culture resulting in inadequate doses of transduced cells for effective therapy. The poor expansion of the T cells appears to be related contamination of the autologous leukocyte apheresis products used as starting material with large quantities of monocytes or granulocytes. We have been evaluating manufacturing methods that make use of lymphocyte enrichment prior to initiating the T cell culture. The methods include plastic adherence, elutriation and CD4/CD8 cell selection. Another limitation of CAR T cell therapy is their limited in vivo survival. In order to improve the in vivo survival and expansion of CAR T cells a GMP method has been developed to isolate, transduce and expand stem memory T cells (Tscm). CD19 CAR Tscm will soon be tested in a clinical trial which will treat adults with B cell malignancies. Limited survival of genetically engineered T cells may also be due to immune reactions to the single chain variable portion of the mouse monoclonal antibody used in the vector. Investigators at our institution have developed a lentiviral vector with humanized anti-CD19 for CAR T cell therapy. Background: Exosomes are endosome-derived nanovesicles involved in intercellar cross-talk through the transfer of proteins and genetic material. Accumulating data suggests that exosomes released from tumor cells may play an essential role in modulating host microenvironment, conditioning tumor immunity both at local and systemic level. We have been collecting evidence that these nanovesicles exert a broad array of detrimental effects on the immune system, such as impairment of monocyte differentiation into dendritic cells and induction of suppressive effectors. Materials and methods: An in vitro model on MDSC conversion from normal monocytes by tumor exosomes (Exo-MDSC) was developed and used to study the molecular pathways involved in MDSC generation. Gene-expression and miRNA profiling of exo-MDSC, blood myeloid cells J Transl Med 2016, 14(Suppl 1):S65 and plasma exosomes isolated from melanoma patients, and in vitro studies with antagonists and mimics, were applied to identify the miR-NAs responsible for exosome-MDSC cross-talk in vitro and in vivo. Results: Compared to untreated monocytes, Exo-MDSC release higher levels of protumorigenic and immunosuppressive cyto/chemokines, down-modulate the expression of HLA-DR and acquire the ability to inhibit T cell proliferation. A gene-expression signature, involving CCL2, IL6 and PD1L, and a defined miRNA profiling have been identified in Exo-MDSC. Using miRNA mimics and inhibitors we demonstrated a strong impact on the regulation of HLA-DR, IL6 and CCL2 for four candidate miRNA, suggesting their involvement in MDSC differentiation. Furthermore, the silencing of these miRNA in melanoma cell lines abrogates exosome conversion potential, sustaining the hypothesis of miRNA transfer via exosomes. Importantly, peripheral blood monocytes from melanoma patients share defined traits of Exo-MDSC gene-expression and miRNA signature, in addition to phenotypic and functional features. In addition, extracellular vesicles isolated from plasma of melanoma patients, but not from healthy donors, induce MDSC conversion ex vivo, and show a higher concentration of myeloconditioning miRNA. Conclusions: Tumor exosomes are involved in triggering MDSC conversion by directly transferring myelo-active miRNAs to myeloid cells. Since MDSC accumulate in peripheral blood of tumor patients in association with disease progression, the identification of exosomes and myelo-conditioning miRNA paves the way for the development of novel immune-based therapeutic strategies and prognostic biomarkers in cancer. Advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations become applicable and effective treatment for many common and deadly cancers. However, a critical limitation in cancer therapy remains the identification of patients likely to respond to a given immunotherapy who could be stratified for treatment. The Society for Immunotherapy of Cancer (SITC) organized workshops and working groups in the past that focused on immune prognostic and predictive biomarkers and immunologic monitoring (1)(2). SITC Taskforce on Immunotherapy Biomarkers developed a series of recommendations and resources for the field (3)(4). Although, the field still lacks standardized and validated biomarkers to identify the patients who are responding to a treatment specific immunotherapies and who will have minimal or acceptable toxicities there are, many promising candidate assays, novel technologies and molecules. Importantly, companion diagnostic assay for response in non-small cell lung cancer have been recently approved by the FDA for patients selection for immunotherapy (PD-L1 IHC 22C3 pharmDx). In light of these developments SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC and discussed during the workshop in April 2016. Specific focus of the talk will be an update from the activity of working group 1 (WG1), led by Drs. Magdalena Thurin and Giuseppe Masucci, focusing on immunologic assays' standardization and validation. This group includes experts from the US National Cancer Institute (NCI), academia, the US FDA, biotech and pharma. They are developing roadmaps for standardization and validation of specific assays that are currently seen as the most promising, particularly with companion diagnostics as the goal. They are also examining proficiency panels of assays, and "integral" and "integrated" (versus exploratory) biomarkers in clinical trials, and statistical designs for biomarker validation.

Background:
The TNM classification from the UICC/AJCC and the guidelines of the WHO 2010 are the basis for the classification of colorectal cancer (CRC). Three clinical scenarios still require novel, reproducible and standardized biomarkers: malignant polyps, stage II CRC with adverse prognosis and the pre-operative management of colon and rectal cancer patients. The immunoscore using immune markers CD3 and CD8 is a promising prognostic approach based on immunohistochemistry and a digital scoring system. Nevertheless, there is still the challenge to implement the immunoscore in daily diagnostic practice in surgical pathology. The aim of this study is to present the results experienced at our Institute of Pathology as one of the participating centers. Materials and methods: The immunoscore (CD3 and CD8) was performed on 331 well characterized CRC patients including the TNM classification, L and V stage, perineuronal infiltration, histological subtype, tumor grade, peritumoral inflammation, mismatch repair status, overall survival and information on adjuvant radio-and chemotherapy using the Roche Benchmark II Ultra and the Definiens Software for the digital pathology analysis. All the tests were performed at the Translational Research Unit (TRU) of the Institute of Pathology, University of Bern. Results: The total turn-around time (TAT) for one case is approximately 15 h including 12 h for immunostaining, 10-20 min for scanning, 30 min for definition of the tumor area and 2 h for calculation. These results demand a well defined working process. Therefore, we elaborated a possible work flow approach based on the LEAN management system: phase 1: CRC diagnosis, block selection and digital order of CD3 and CD8 by the pathologist; phase 2: immunohistochemical staining and scanning by the immunohistochemistry laboratory; phase 3: definition of the tumor area, calculation and reporting of the results by the pathologist; phase 4: discussion of the results at the interdisciplinary CRC board.

Conclusions:
The implementation of the immunoscore in surgical pathology on the operative level needs a well defined strategy which is simple, applicable and user-friendly. Therefore, based on our experience well defined working processes based on SOPs and TATs in the surgical pathology divisions and digital pathology development units which test novel and promising digital scoring systems before the implementation in the daily diagnostic practice should be considered. We provided evidence that the type, the density and the location of immune cells within colonic tumor strongly influence the prognosis, independently of the TNM classification [1][2][3][4]. Thus, the adaptive immune reaction composed of T lymphocytes (CD3) with cytotoxic (CD8) and memory (CD45RO) phenotype within the core of the tumor (CT) and the invasive margin (IM) is a highly significant parameter to predict recurrence and survival. Multivariate analyses have revealed that T cell-immune parameters not only remain meaningful when combined with the TNM staging system but also were shown to be more accurate in determining prognosis than are conventional clinicopathological criteria. These data strongly suggests that tumor behavior should now be considered as the result of a balance between the invasive tumor process and the response of the host of which the local immune reaction is a major component. We established a methodology named "Immunoscore" to assess in clinical practice the immune infiltrate. Each tumor is categorized into Hi or Lo density for each marker in each tumor region, according to a predetermined cut-off value using the minimum P value approach. Patients are stratified according to a score ranging from I0 to I4 depending on the total number of high densities observed (two markers assessed in CT, two markers assessed in IM). For example, I4 refers to a tumor with high densities of CD3 and CD8 cells in CT and IM regions. We recently applied this classification in patients with clinically localized rectal cancer treated by primary surgery [5] and showed that the Immunoscore could be a useful prognostic marker. Cox multivariate analysis supports the advantage of the Immunoscore compared with the tumor-node-metastasis (TNM) staging in predicting recurrence and survival and the lymph node ratio (LNR) added information in the prognostic model. The information carried by the LNR could reflect complementary aspects of the antitumor immunity not depicted by the Immunoscore. In an effort to promote use of the Immunoscore in routine clinical settings, an international task force was initiated, supported by the Society for Immunotherapy of Cancer (SITC) [6]. An independent international panel of expert laboratories has started to work on large retrospective cohorts of colonic cancers (TNM stage I-III) to test the Immunoscore in routine clinical settings. The availability of the Immunoscore could significantly improve the prognostic assessment of patients and better guide the therapeutic decision, and possibly choosing patients likely to benefit from immunotherapy. Background: Each year in Europe, 62,000 new cases of melanoma are diagnosed. DTIC was considered the Standard of Care until the appearance of two new classes of compounds in the treatment of metastatic melanoma. These drugs were a CTLA-4 blocking antibody and the therapies targeting the BRAF kinase pathways. Recently, Nivolumab a highly specific programmed death-1 (PD-1) checkpoint inhibitor has been authorised [1]. In this oral communication, the regulatory experience with nivolumab is reviewed. Materials and methods: European public assessment report (a set of documents describing the evaluation of a medicine authorised via the centralised procedure) and the publications of the clinical trials of nivolumab, will be the basis for the review. Results: The background for the authorisation of nivolumab in the treatment of subjects with advanced melanoma were two different studies: study CA209037 [2,3]: a phase 3 trial of nivolumab vs investigator's choice in advanced Melanoma patients progressing post anti-CTLA-4 therapy; and Study CA209069 [2,4]: a phase 3, study of nivolumab vs dacarbazine in subjects with BRAF wild type, previously untreated. Nivolumab shown convincing statistically significant and clinically relevant results in the first-line treatment of metastatic melanoma. Unfortunately, mature data on OS are not available, since only 34 % of the events have occurred. However, it seems reasonable to assume that the higher life expectancy associated to nivolumab in first line will be maintained. Regarding the use of nivolumab in last line, after failure of ipilimumab and/or BRAF inhibitors, positive results have been observed for ORR and PFS although limited to a subset of patients. However, the OS curves show an unexpected profile with the lines crossing between 6 and 9 months. It seems plausible that the delay in the onset of the effect of nivolumab (3 months) contributes to the higher rate of deaths in the nivolumab arm in the first 3 months of treatment. This effect has been also observed in the treatment of non-squamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy [5]. On the contrary, the same molecule has shown a clear benefit in survival in squamous NSCLC [6,7]. Conclusions: The use of nivolumab in some patients might mean a worse option than chemotherapy. It remains a challenge to identify those patients who could have a chance to benefit from nivolumab.
Background: Interest in onco immunotherapies has been growing in last years, due to market launch of ipilimumab for advanced melanoma. Ipilimumab provides important benefits, but is also very costly (1,2). Its incremental cost-effectiveness is over thresholds and closer to the 50 k Euro per life-year saved threshold if US list prices (3) and European prices (4) are respectively used. NICE recommended ipilimumab with a hidden discount on list price. Drugs pipelines include many new onco immunotherapy. An assessment framework of their value for money is needed for managing their future market access (reimbursement/price/recommendation). The present research aims at providing some pillars of this framework.

Materials and methods:
The study follows a Delphi methodology, a technique used to facilitate information-gathering on complex issues (5). More specifically, we relied on a e-Delphi (6) organized in three rounds and involving nine experts, including clinicians, health economists and payers. Panelists were asked to comment on ten statements, explaining the extent to which they agreed or disagreed with assertions. Statements were subsequently modified and resubmitted for a final consensus. Results: This paragraph quotes six of the ten statements. The other four specifically concern the Italian context. (i) Medium-long term survival is the most appropriate endpoint to consider for market access of onco immunotherapies. Progression Free Survival and Best Overall Response Rate do not fully express benefits and immuno-related surrogate endpoints still need surrogacy validation. (ii) More specifically, the increase in 2-5 years probability of survival is the most important indicator. Quality of life and adverse events should be also considered. (iii) Market access would be easier managed if methods requirements (endpoints, indicators, follow-up, statistical analysis) are strengthened. (iv) Cost-effectiveness used for market access purposes should rely on robust extrapolation of future survival; results provided by the industry should be validated by independent research groups; incremental cost-effectiveness ratio thresholds should be carefully applied; cost-effectiveness should be integrated with a budget impact analysis. (v) Coverage with evidence development agreements should be implemented, due to benefits long-term and uncertainty: this requires post-approval evidence on survival, quality of life and costs. (vi) Longterm survival predictive factors would be extremely useful to enhance sustainability, provided that they actually reduce uncertainty. Manufacturer funded treatment initiation may be applied for expected nonresponders. However clinical research has not found reliable markers for onco immunotherapies yet. Background: Blocking the immune checkpoint molecule Cytotoxic T-lymphocyte antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients with metastatic melanoma. Although the theoretic base for the success of this therapy has been described, the detailed mechanisms involved are not yet fully understood. In addition to this, there is a great need of predictive, prognostic and pharmacodynamic biomarkers that may allow clinicians to screen for immune related adverse events and potentially provide information for patient preselection. In this study we show the results derived from the immune monitoring of advanced melanoma patients undergoing treatment with ipilimumab. Materials and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 42 melanoma patients at three time points before and during treatment. PBMCs were stained with 12 multi-color flow cytometric panels within 2 h of sample collection.

Results:
The results show that ipilimumab treatment contributes to activate CD 4 T cells as is shown by a significant increase in the frequency of ICOS + CD4 cells. This increase is correlated with a decrease in the frequency of granulocytic MDSCs (grMDSCs) and their suppressive potential, determined by their intracellular Arg1 levels. In contrast to these results, monocytic MDSC (moMDSC) frequency was not affected by CTLA-4 blockade, but the frequency of iNOS + cells within this MDSC subset was diminished. This suggests that that at least one of the suppressive mechanisms used by moMDSCs is impaired. Regulatory T cells (Tregs) were also reduced, although their pattern did not correlate with MDSC or activated T cell frequency. In the 42 patients included, median OS was 55 weeks from the start of treatment. Adverse events were observed in 16 patients (38 %), including eight grade III-IV (19 %). Patients were classified according to their response as PD (progressive disease, 57 %), SD (stable disease, 23 %) and PR (partial response, 20 %). Possible correlations between treatment outcome and MDSC frequencies are currently being evaluated as the patient cohort increases. Conclusions: These results suggest that there may be more than one mechanism of action by which ipilimumab releases the brake on the immune system. On one hand, blocking CTLA-4 results in an in cis effect on the activation status of CD4+ T cells. On the other hand the observed reduction in Tregs and MDSCs (in frequency and suppressive potential) may contribute to significantly alleviate the suppression exerted on the immune system. These effects and their possible clinical implications should be further explored in order to fully understand the mechanisms of action of CTLA-4 blockade with ipilimumab. Background: The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in drug-naive BRAF V600 mutation-positive metastatic melanoma patients. Vemurafenib has shown a 74 % reduction in the risk for death or disease progression and a 63 % reduction in the risk for death compared with dacarbazine (P < 0.001 for both comparisons). Materials and methods: Patients were randomly assigned to receive vemurafenib (960 mg BID) or dacarbazine (1000 mg/m 2 every 3 week). OS and PFS were coprimary end points. OS was assessed in the intention-to-treat population, with and without censoring of data for dacarbazine patients who crossed over to vemurafenib. Effects of age, disease stage, baseline lactate dehydrogenase value, baseline Eastern Cooperative Oncology Group performance status (ECOG PS) value, and prior therapies were also analyzed by treatment received. Results: A total of 675 patients were randomly assigned to receive vemurafenib (n = 337) or dacarbazine (n = 338). At the time of database lock (Aug 14, 2015), median follow-up was 13.37 months (range 0.4-59.6) for vemurafenib and 9.15 months (range 0-56.2) for dacarbazine. Of 338 patients initially randomly assigned to receive dacarbazine, 84 crossed over to vemurafenib. Subgroup analyses and final OS data will be presented. Background: The phase 3 study CheckMate 067 (NCT01844505) showed improved progression-free survival (PFS) and objective response rate (ORR) by RECIST v1.1 for NIVO (anti-PD-1) + IPI (anti-CTLA-4) (median 11.5 months [mo], 58 %) or NIVO (6.9 months, 44 %) compared with IPI (2.9 months, 19 %) in patients (pts) with previously untreated advanced melanoma [1]; however, long-term follow-up data including overall survival (OS) are not yet available. Updated data from CA209-004 (NCT01024231) in pts with unresectable or metastatic melanoma are reported here. Materials and methods: Cohorts [C] 1, 2, 2a, and 3 received NIVO + IPI Q3W × 4 followed by NIVO Q3W × 4; pts without progressive disease or dose-limiting toxicity received NIVO + IPI Q12W × 8. An expansion cohort (C8) received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4 followed by NIVO 3 mg/kg Q2W (regimen used in phase 2/3 trials). Data are reported for C1-3 (n = 53) and C8 (n = 41). Results: 40 % of pts in C1-3 and 51 % of pts in C8 were previously treated. At a median follow-up of 32.7 months (range: 2.5-61.4) for C1-3 and 19.9 months (range: 0.9-24.0) for C8, ORR by mWHO criteria was 42 and 44 %, respectively, and the median duration of response was 22.3 and 13.8 months. Complete response was seen in 21 % of pts in C1-3 and 17 % of pts in C8, and the median tumor burden reduction was 70 and 58 %, respectively. OS rates were 79 % at 24 months in C1-3 and 68 % at 18 months in C8. PFS rates were 30 % at 24 months in C1-3 and 27 % at 18 months in C8. Incidence of drug-related adverse events (AEs) was 56 % for grade 3/4 AEs and 39 % for grade 3/4 select AEs in C1-3 and C8 combined (n = 94). Conclusions: OS for concurrent NIVO + IPI was higher than expected for each agent alone in this population, with a manageable safety profile. Reused with permission from the Society for Melanoma Research (SMR) and all authors.  Background: The primary analysis of coBRIM showed superior progression-free survival (PFS) for COBI + VEM in advanced BRAF-mutated melanoma pts [1]. We present the protocol-defined, updated PFS analysis and final OS analysis and correlate these efficacy results to key biomarkers. Materials and methods: coBRIM has been described previously [1]. Pts were randomly assigned to receive COBI + VEM or PBO + VEM. Primary endpoint was investigator-assessed PFS; overall survival (OS) was a secondary endpoint. Following the primary PFS analysis, coBRIM remained blinded, and pts were followed up for OS. Final OS analysis occurred after 250 events. For biomarker analysis, pretreatment tumor samples were evaluated for BRAF V600 allele frequency (BRAF V600 copy number) by targeted deep sequencing and pathway activation by pERK, pS6, and PTEN, and Ki67 by immunohistochemistry. Cox proportional hazards models were used to assess the association between OS and biomarkers. resulting in a rapid clinical response. The durability of response can potentially be further extended by combining V and atezolizumab (A; MPDL3280A), which may enhance and perpetuate antitumor immune activity. Materials and methods: Patients with untreated BRAF V600 -mutant unresectable or metastatic melanoma received A + V combination concurrently (cohort 1 [C1], n = 3) or after a run-in period with V alone (56 days for cohort 2 [C2, n = 8]; 28 days for cohort 3 [C3, n = 6]). Administration of A was IV q3w at 20 mg/kg (C1) and 15 mg/kg or 1200 mg fixed (C2 and C3). V was administered orally BID 960 mg during run-in and 720 mg during the A + V combination period. PD-L1 expression on tumor cells and tumor-infiltrating immune cells was centrally examined by immunohistochemistry (SP142 assay). Results: Of 19 BRAF inhibitor-and immunotherapy-naive patients enrolled, 17 who received ≥1 dose of A were safety and efficacy evaluable (data cutoff, Mar 16, 2015). Across cohorts, 65 % of patients were male and median age was 53 y (range, 30-71 y). Patients received A + V combination for a median of 8.5 months (range, 1.2-27.8 months). Median safety follow-up (mo) was 6.5 (C1), 10.6 (C2) and 10.4 (C3). A + V did not result in any DLTs or unexpected AEs. Incidence of A-or V-related G3 AEs was 41 and 59 %, respectively, and was higher in C1 (67 % A; 100 % V) than in C2 (38 % A; 50 % V) or C3 (33 % A; 50 % V). AEs were manageable and generally reversible. Related G4 AEs were absent. No G5 AEs occurred. There were no A-related AEs leading to treatment discontinuation; 1 patient in C1 had V-related AEs leading to discontinuation. Clinical activity results are presented in Table 1. Higher ORR was seen with V run-in (C2, 75 %; C3, 100 %) than with concurrent A + V start (C1, 33 %). Preliminary data indicate an increase in PD-L1 expression in repeat biopsies after V run-in or A + V combination, suggesting induction of an enhanced antitumor immune response. Conclusions: Overall, a manageable safety profile and promising antitumor activity were demonstrated with A + V combination therapy. In particular, staggered dosing of A with V run-in was better tolerated and yielded high rates of durable response. Triple-combination therapy with A + V+cobimetinib (MEK inhibitor) in this patient population is under investigation. (NCT01656642).
Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophancatabolizing enzyme that induces immune tolerance by suppressing T-cell responses. Epacadostat is a potent, selective oral IDO1 inhibitor. In a dose-escalation study in patients with metastatic melanoma, the combination of epacadostat with ipilimumab was generally tolerated and favorable response rates were observed in immunotherapy-naive patients. Materials and methods: NCT02178722 is an ongoing study of epacadostat with pembrolizumab in patients with advanced melanoma and other cancers with a 3 + 3+ 3 phase 1 design. Patients previously treated with checkpoint inhibitors were excluded. During dose-escalation, patients received epacadostat 25, 50, or 100 mg BID with pembrolizumab 2 mg/kg IV every 3 weeks or epacadostat 300 mg BID with pembrolizumab 200 mg IV every 3 weeks. During dose-expansion, patients received epacadostat 50, 100, or 300 mg BID with pembrolizumab 200 mg IV every 3 weeks. Safety, tolerability, and investigatorassessed tumor response (RECIST 1.1) were evaluated. Results: As of 29 Oct 2015, 62 patients were enrolled. Safety data on 56 patients with either melanoma (n = 20), RCC (n = 11), NSCLC (n = 10), transitional cell carcinoma (n = 5), endometrial adenocarcinoma (n = 5), TNBC (n = 3), or SCCHN (n = 2) as of October 1, 2015 are presented. The most common all grade treatment-related AEs were rash (25 %), fatigue (23 %), arthralgia (13 %), pruritus (13 %), nausea (11 %), and pyrexia (11 %). Grade 3 treatment-related AEs occurred in 11 % of patients; the most common grade 3 treatmentrelated AE was rash (5 %). There were no grade 4 treatment-related AEs and no treatment-related deaths. One patient discontinued for a treatment-related AE (grade 3 AST elevation). In 19 efficacy evaluable melanoma patients, ORR was 53 % and disease control rate was 74 % (3 CRs, 7 PRs, 4 SDs). Responses occurred in patients who were PD-L1-positive and PD-L1-negative (PD-L1 IHC 22C3 pharmDx Kit; ≥1 % cutoff for positivity). All responses are ongoing as of the data cutoff. Conclusion: Preliminary safety data support continued evaluation of epacadostat with pembrolizumab. Although preliminary, the efficacy data suggest promising clinical activity of the combination in patients with advanced/metastatic melanoma. Updated safety data will be presented. Background: About 50 % of metastatic melanomas (MM) harbour mutations in the BRAF gene, mainly at codon 600, resulting in constitutive activation of the MAPK pathway [1]. The selective inhibitors of BRAF V600, vemurafenib and dabrafenib have shown major tumor responses in about 50 % of patients. However, the majority of patients progress after 6-8 months due to several resistance mechanisms which are only partially understood. As both targeting agents appear to benefit only certain subsets of patients, the identification of predictors of response is mandatory. One of the available strategies that facilitates the simultaneous analysis of a large number of factors in biological material is surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI ToF MS). The purpose of the present study is to verify if this high-throughput technique is able to individuate novel candidate peptides useful as biomarkers to predict the response or resistance to BRAF inhibitors. Moreover, we integrated results of our recent study [2] regarding the relationship between microRNA expression and response to Vemurafenib in order to better understand biological mechanism influencing disease progression. Materials and methods: In order to discover novel candidate biomarkers predictive to treatment, serum of 39 MM vemurafenib treated patients at baseline, at disease control and at progression, were analyzed using SELDI-TOF technology. The Mascot Peptide Mass Fingerprint online tool (http://www.matrixscience.com/cgi/search_form. pl?FORMVER52&SEARCH5PMF) was used to identify more significant peaks and miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mir-walk2/index.html) to verify interaction between microRNA and genes coding for the predicted proteins. Results: At baseline as predictive biomarkers we identified four peaks-m/z 5900, 12544, 49124 and 11724-significantly up-regulated in longer versus shorter responders to vemurafenib. After response, three peptides m/z 9292, 7765 and 9176 appeared up-regulated in responder patients. In silico predictions indicated that the metastatic suppressor gene KLF17 and two cellular proteins, RBM10 and TOX3, which are involved in proliferation and apoptosis of cancer cells, could be the actors influencing the outcome of BRAF inhibitor therapy. TOX3, RMB10 and KLF17 resulted target of miR-132-3P, the miRNA whose lower expression is associated to shorter progression free survival.

Conclusions:
In conclusion, our results highlighted the possibility to better stratify patients that could be addressed to BRAF inhibitor therapy. Moreover, the combined analysis of epigenetic, microRNAs, and proteomic data could help to uncover the biological mechanism of resistance in MM.

Background:
The prognosis of a variety of human malignancies including melanoma is dictated by the abundance, spatial trafficking and quality of intratumoral T cell infiltrates [1]. Salerno and al. recently studied chemokine receptors (CC/CXCR) expression on Tumor-Infiltrating T cells (TILs) from several metastasis localizations and suggest a limited tissue-specific homing to human melanoma [2]. We studied the expression of these CC/CXCR on peripheral T cells from metastatic melanoma (MM) patients, during Ipilimumab therapy and healthy volunteers (HV). We found an orchestrated deregulation of these molecules according to the various sites of disease dissemination. Moreover, we discovered some putative biomarkers of response to Ipilimumab before and during the therapy such as the amount of CD4 and CD8 + CLA + effector memory T cells.

Materials and methods:
We assessed this chemokine receptors profiling on 57 cryopreserved blood samples from stage III/IV melanoma patients and on 26 HV. Moreover, 47 patients treated with Ipilimumab and enrolled in four clinical centers (France, Germany, Italy and USA) were studied. We performed flow cytometric analysis of CD4 and CD8 T cells subsets based on their expression of CCR7 and CD45RA and then assessed, for each subset, the expression of CLA, CXCR5, CRTH2, CCR10, CD103, CCR9, CXCR4, CXCR3 and CCR6. Results: Firstly, correlation matrices indicated similar chemokine receptor expression on CD4 and CD8 T cells, except for CXCR4 and CD103, and concordant patterns in naïve, effector and memory T cells. After classification of patients based on their metastasis localizations with skin and lymph node, lung or other distant organs with or without lung involvement, 62 parameters were found to differ significantly (FDR < 0.1) according to distinct localizations metastasis. Expression level normalized with respect to HV indicated that specific signatures could identify preferential metastasis localizations. Loss of CCR6 or CXCR3 (but not CLA) on circulating T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5 and CCR9 with lung involvement, and a raise in CCR10 or CD103 with widespread dissemination. High frequencies of CD8 + CCR9 + TN correlated with prolonged OS (p < 10 −4 ), while neutralizing the CCR9/CCL25 axis in mice stimulated tumor progression. Effector memory CD4 + and CD8 + expressing CLA increased upon CTLA4 blockade, both predicting disease control at 3 months of therapy in 47 MM.

Conclusion:
We discovered an immune chemokine receptor profile which mirrors the metastatic pattern of the disease and highlighted new pharmacodynamic parameters during immune checkpoint blockade with Ipilimumab. Background: Although Ipilimumab (IPI) definitely improves the PFS and extends the OS in metastatic melanoma [1], the immunologic criteria for both evaluation and prediction of the therapeutic response are presently uncertain in clinical management of patients. Recently, both melanoma [2] and immune cells [3] have been described to release exosomes (Exo), namely endomysial microvesicles with antigenic and molecular features resembling the original phenotype pattern of the producing cell [4]. Thus, serum levels of Exo may indirectly reflect the response to IPI immunotherapy and detection of both CD28 and PD1 expressed by T cell-released Exo in sera of IPI-treated patients may identify the responders, suggesting Exo measurement as a potential tool to evaluate the immune response against melanoma. Materials and methods: Sixty patients with advanced melanoma in treatment with IPI were enrolled. Sera were collected both before and after the four-month treatment, and Exo were purified by the "Total Exosome Isolation kit" (Invitrogen, Carlsbad, California). Thus, they were investigated by flow-cytometry in their expression of PD1, CD28, ICOS by gating the CD3 + cells and CD86 with the purpose to identify Exo released by dendritic cells (DEX). Therefore, median levels of PD1-, CD28-and ICOS-positive Exo were calculated both at baseline and longitudinally and compared with the therapeutic response by waterfall chart. Finally, both PFS and OS were calculated by Kaplan-Meier regression analyses.

Results:
The therapeutic response to IPI as disease stability, partial or complete response, associated with PFS improvement and favourable trend of OS, was detected in 12 patients. Data from Exo investigation revealed higher expression of both PD1 and CD28 before IPI J Transl Med 2016, 14(Suppl 1):S65 (p = 0.03; and 0.008 respectively), whereas the ICOS level expression remained mostly unchanged. By contrast, the major group of patients with disease progression showed minimal levels of either PD1-, or CD28-positive Exo. Interestingly, we found in IPI-responsive patients a quantitative increase of DEX after completion of the immunotherapy treatment (p < 0.01). Thus, we interpreted this finding as effect of the anti-melanoma immune activation. Conclusions: Our data suggest that higher levels of PD1-and CD28positive Exo in sera of melanoma patients before undergoing IPI treatment may predict the anti-melanoma immune activation induced by IPI and that the measurement of these molecular biomarkers could early identify the melanoma patients responsive to immunotherapy.
Background: Stage III melanomas (MM) require adequate adjuvant immunotherapy to prevent relapses. The magnitude of metastatic lymph node (mLN) invasion and a BRAF V600 activating mutation have a clinical significance; however, prognostic factors are awaited to optimize the clinical management of these patients.

Materials and methods:
We performed a comprehensive immunophenotyping of 252 parameters/patient by flow cytometry and ELISA techniques, in paired blood and mLN performed in 39 metastatic melanomas. Wilcoxon signed-rank test was applied to assess differences in concentration between matching pairs of blood leukocytes and tumor infiltrated cells samples. Overall Survival (OS) and Relapse Free Survival (RFS) determined from the date of sampling were used as the primary end-points. Survival curves were estimated by the Kaplan-Meier product-limit method. Results: We found immunotypes corresponding to clinical presentations. mLN extensive invasion was associated with lower levels of circulating CD4 + T cells and lower expressions of CD137L on CD3 − CD56 − cells and PD1 on CD8 + , in blood and TILs, respectively. BRAF mutation was associated with higher levels of CD45RA + CD4 + TILs and lower expression of CD137L on circulating CD8 + and NK cells. High frequencies of tumoral CD45RA + CD4 + and CD3 − CD56 − TILs were independent prognostic factors of short RFS, and remained significant after adjusting for mLN invasion, therefore adding prognostic value to local aggressiveness. The best predictive markers of OS after adjusting for significant clinical variables included NKG2D expression levels on intratumoral CTLs, intratumoral Tregs infiltration, and PD-L1 intensity on blood T cells. When combined with BRAF mutation, very high percentages of NKG2D + CD8 + TILs or low percentages of Tregs protected against the BRAF mutation-associated dismal prognosis. In blood, high expression levels of PD-L1 on CD4 + and CD8 + T lymphocytes were associated with a bad prognosis, also adding value to the BRAF mutational status. Conclusions: Overall, when classifying our 252 immunological markers determined in blood and tumor beds according to their biological and clinical significance in stage III MM, we concluded that (i) both blood and tumor markers equally contributed to defining the prognosis, (ii) exhaustion markers markedly affected the clinical outcome and (iii) activation markers appeared less relevant for the functional study of tumor beds. Only six markers were found to be significant prognostic factors influencing RFS or OS in blood or tumor beds independently of clinicopathological parameters in multivariate Cox regression analyses. These immunotypes deserve to be followed in the course of the development of monoclonal antibody therapies. J Transl Med 2016, 14(Suppl 1):S65 melanoma cells resistant to single B-RAF and combined with MEK inhibition is critical for therapeutic exploitation.

Materials and methods: Melanoma cell lines, resistant to B-RAF inhibitors (B-RAFi) as single agent or combined with MEK inhibitors (MEKi),
were selected by growing them in medium containing increased concentrations of B-RAF inhibitors (B-RAFi: GSK2118436) alone or combined MEK inhibitors (MEKi: GSK1120212). Morphological and phenotypic investigation was performed by light microscopy, immunofluorescence and flow cytometer analysis. Results: Here, we detected a cell subset inside of three different melanoma cell lines, deriving from patients with B-RAF (V600E) mutant metastatic melanoma. This cell-subset was able to proliferate and forming colonies at low density in presence of single B-RAF inhibitors (B-RAFi) or combined with MEK inhibitors (MEKi), suggesting that drug treatment was unable to kill all the cells, but few of them continued to grow forming sizeable colonies as the ones observed from untreated cells. We enriched this cell-subset, by growing them in drugs and we characterized them by measuring drug IC50 and examining the effect of the drug on the cell cycle, by flow cytometer. Successively, we investigated their morphological and phenotypic properties. We found that melanoma cells, resistant to B-RAFi alone or combined with MEKi, exhibited a bigger cellular body, an increased inter-cellular space and the pseudopodia formation compared to their sensitive counterparts. FACS analysis of CD90 and CD324 markers revealed an increased expression of CD90 with a reduction of CD324 in resistant cells. In addition, the drug resistant cells were able to attach and spread on the plate, in a 3D culture system, while the sensitive ones were unable to do it. We also found a reorganization of the network of vimentin mainly localized at perinuclear sites in the drug resistant cells. All together these data supported a mesenchymal-like phenotype of the melanoma cells, resistant to B-RAFi alone or combined with MEKi. Conclusions: These data suggest that melanoma cells contained a cell-subset with mesenchymal-like features that were resistant to B-RAFi and MEKi drugs [2]. Further characterization of these cells will help to define novel targets opening up the possibility to develop efficacious therapeutic strategies and contributing to overcome the big issue of drug resistance in melanoma.
Background: Despite novel therapeutic treatments developed in recent years, advanced melanoma patients continue to die. Therefore, the development of efficacious therapeutic strategies to prevent or delay the onset of resistance mechanism in melanoma, is fundamental. ABT888 is a potential anti-cancer drug being evaluated in multiple tumor types; it acts as a poly-(ADP-Ribose) polymerases (PARP) inhibitor, nuclear enzymes that repairs damage to DNA. Through inhibition of PARP, ABT888 helps to prevent DNA repair in cancer cells, leading to cell death [1]. In the current study, we tested the anti-proliferative and pro-apoptotic action of ABT888 on the melanoma cell line A375

Conclusions:
In this study we observe that ABT888 exhibited its antiproliferative and pro-apoptotic activity on melanoma cell lines. Interesting, we found that ABT888 was able to kill melanoma cells resistant to B-RAF inhibitor (Dabrafenib). This results suggest that ABT888 may represent a promising therapeutic approach for melanomas that have developed resistance against some molecular targeted inhibitors. Further studies will be performed to assess whether the combination of B-RAF and PARP inhibitors can prevent or delay the onset of resistance mechanism in melanoma. J Transl Med 2016, 14(Suppl 1):S65 investigated the role of H 2 S in triggering cell death and evidence has been presented that this gas can exert both pro-and anti-apoptotic activity in cultured cells [3,4]. Recently, CBS has emerged as a potential therapeutic target in both colon cancer and ovarian cancer [5,6]. The aim of our study was to evaluate the role of the metabolic H 2 S pathway in human melanoma. Methods: We utilized cell culture, immunohistochemistry, molecular biology techniques and mice melanoma model.
Results: Using immunohistochemistry we demonstrated the presence of the l-cysteine/CSE/H 2 S pathway in human melanoma specimens and provided evidence that CSE expression was highest in primary tumors while decreased in the metastatic lesions and it was almost silent in non lymph node metastases. Conversely, CBS did not appear to play an important role in melanoma. The role of CSE and the downstream signal transduction were investigated by using several human melanoma cell lines. The primary role played by CSE, already revealed by the human study, was confirmed by the finding that the over-expression of CSE induced spontaneous apoptosis of human melanoma cells (30 %; P < 0.001 vs mock transfected cells). The same effect was achieved by using different H 2 S donors and, among them, the most active resulted to be diallyl trisulfide (DATS) (IC 50 = 89 μM).
The main pro-apoptotic mechanisms involved were suppression of nuclear factor-κB activity and inhibition of AKT and ERK1/2 pathways. A proof of concept was obtained in vivo by using a murine melanoma model. In fact, either l-cysteine, the CSE substrate, or DATS inhibited tumor growth by 51 % and by 67 % respectively (P < 0.001, n = 8).

Conclusion:
In conclusion, this work establishes that the l-cysteine/ CSE/H 2 S pathway is involved in human melanoma and provide the fundamentals to exploit a possible therapeutic/diagnostic use in this aggressive disease.
Background: Revealing cancer stem cells (CSC) is a major issue for effective cancer therapeutics. We postulated that an immunoglobulin (Ig) repertoire analysis and investigating freshly removed cancerous tissues would serve this aim. Our focus was kept on the natural humoral immune response, having the capacity to recognize modified oligosaccharide expression patterns, characteristic for cancer.

Materials and methods:
In the course of a tumorimmunological study primary and metastatic tumors as well as peripheral blood samples of patients with malignant melanoma (n = 123) were investigated in terms of antibody repertoire. Heavy (VH) and light chain (VL) Ig variable region gene fragments were amplified by polymerase chain reaction and VH and VL were adjoined by a [(Gly)4Ser] 3 linker for the single chain Fv (scFv) construct. Two technical approaches for scFv phage display library (1) generation were standardised. A column purification process was used to get enriched immunoglobulins for binding assays (2). Comparative DNA sequence analyses and antibody phage enzymelinked immunosorbence assay (ELISA) with native membrane preparations were done.

Results:
The expressed immunoglobulin variable region gene usage in the VH3 family represented the VH3-23 and VH3-21 overexpression, and revealed that sequences were frequently in a germline configuration with a low replacement to silent ratio of mutations. Among the representative Ig clusters a cancer stem cell-associated CD34 and GD3 disialylated glycosphingolipid-targetting pattern could be defined. Using native membrane preparations and primary cultures from the tumor was found to be ideal to reveal novel cancer cell characteristics and antibody fragments with CSC binding potential. Conclusions: Our technology helps to understand and harness the miscellaneous field of human antibody repertoire composition in malignant diseases, compared to autoimmune and normal conditions. The present data show unique potentials of tumor infiltrating B cellderived antibodies to reveal cancer stem cell characteristics and would serve for novel diagnostic and therapeutic developments. J Transl Med 2016, 14(Suppl 1):S65 exposure. Two alternative modes of ErbB3 activation have been proposed: the first involves FOXD3-dependent transcriptional activation of ErbB3 and increased cell sensitization to exogenous ErbB3 ligand neuregulin (NRG1); the second increased NRG1 production and autocrine activation of ErbB3. The present study was undertaken to provide better insights into these two alternative mechanisms. Materials and methods: BRAF-mutated melanoma cell lines M14, A375 and LOX-IMVI (BRAF V600E), WM115 and WM266 (BRAF V600D) were exposed to BRAFi and/or MEKi treatments at different times. mRNA expression levels were assessed by Real Time PCR. Western blot analysis was performed on total protein extracts from untreated and treated cells. NRG-1 in melanoma cell media was assessed using Bio-Plex Pro NRG-1 Assays (Bio-Rad). Results: Melanoma cells were treated with BRAFi and/or MEKi for different times (2-72 h) and changes in gene expression levels of NRG-1, ErbB3 and FOXD3 were determined. We observed two different patterns. In the first case exemplified by M14 and A375 cells we detected simultaneous increases in mRNA levels of NRG-1, FOXD3 and (to a lower extent) ErbB3 only at late times after drug exposure. Surprisingly, the late increase of NRG-1 mRNA expression was not accompanied by increase in the secretion of the cytokine in the cell medium.
In contrast in WM266 cells a sharp increase of NRG1 and to a lower extent of FOXD3 without changes in ErbB3 was observed early after drug exposure. In line with this last finding we were able to detect up to thousand -fold increase in secreted neuregulin-1 in cell media of WM266 shortly after drug exposure. Conclusions: Our preliminary results show that a constant feature of melanoma cells exposed to drugs that inhibit the BRAF/MEK axis is the increased expression of NRG-1, albeit with different kinetics in different cells. Interestingly increased expression is not always accompanied by increased cytokine secretion. We are currently performing transfections with NRG-1 promoter luciferase fusion in order to provide new insights on the transcriptional regulation of this gene upon drug exposure. Background: HuR is a ubiquitously expressed member of the Hu family that contains three RNA-recognition motifs with the ability to bind adenylate-and uridylate-rich elements (AREs) in target mRNA [1]. These AREs are usually located in the 3′UTR of target transcripts, and the binding of HuR largely results in mRNA stabilization and/ or increased translation [2,3]. Furthermore, aberrant HuR expression has been reported in malignancies such as colon, breast and prostate cancer [4, 5, 6,]. Among the many established HuR targets are the transcripts of genes involved in cancer and inflammation, including COX-2 and MMP-9 [7]. Using cutting-edge PAR-CLIP technique, Lebedeva et al. demonstrated RBP HuR binding sites in WNT5A mRNA, in the transcriptome of HeLa cells [8]. Overexpression of WNT5A plays a significant role in melanoma cancer progression; however, the mechanism(s) involved remains unknown.
In the present study, we investigated if RNA-binding protein HuR interacts with WNT5A mRNA thereby regulating its expression. We also delineated the functional consequences of such interaction by studying its impact on melanoma cell migration.

Materials and methods:
To identify HuR-WNT5A mRNA interaction, HuR-RNA binding protein immunoprecipitation (RIP) assay and WNT5A 3′UTR luciferase assay were carried out. HuR-WNT5A association studies were investigated via siRNA knockdown of HuR and short-term treatment with the low molecular weight HuR inhibitor, MS-444. To investigate functional consequences of HuR-WNT5A interactions on melanoma cell migration, we performed trans-well cell migration assays.

Results:
We selected HTB63 as a model cell line for our study for two reasons. Firstly, it expresses WNT5A protein endogenously and secondly, according to HOPP algorithm it is characterized as invasive cell phenotype. We found that endogenous expression of WNT5A correlates with levels of active HuR in these cells. We further demonstrated that HuR protein binds to 3′ UTR of WNT5A mRNA in HTB63 cells. HuR inhibition either via siRNA knockdown or by MS-444 treatment resulted in significant inhibition of WNT5A mRNA and protein levels in these cells. Finally, we demonstrated that MS-444 treatment significantly inhibited migration of HTB63 cells in WNT5A-dependent fashion, as MS-444-induced inhibition was restored by the addition of recombinant WNT5A. Conclusions: HuR protein binds to 3′UTR of WNT5A mRNA and governs HTB63 melanoma cell migration via up-regulating WNT5A protein expression.
Background: Alterations in the properties of the basement membrane are a recognized feature of cancer cells. Collagen, the principal structural component, must undergo appropriate post-translational processing for efficient function and this requires prolyl hydroxylation, catalyzed by the prolyl 3-(C-P3H) and prolyl 4-(C-P4H) hydroxylases, which have multiple family members in the human genome. Materials and methods: Using qPCR, western blotting and pyrosequencing, we have investigated the expression and transcriptional regulation, by means of CpG Island methylation, in the C-P4H family in melanoma cell lines and in clinical cases of melanoma including primary and metastatic lesions, both in tissues and in sera.
To seek mechanistic correlates of the proposed differences between P4HA1/P4HA2 and P4HA3, we modulated expression of P4HA2 and P4HA3 in melanoma cell lines using ectopic expression and knock-down. J Transl Med 2016, 14(Suppl 1):S65

Results:
We show that the C-P4Hs P4HA1 and P4HA2 are invariably unmethylated and often over-expressed in melanoma, whereas P4HA3 is subject to methylation-dependent transcriptional silencing in primary and particularly metastatic melanoma. Ectopic expression of P4HA2 and P4HA3 has opposing effects on melanoma growth, P4HA2 promoting and P4HA3 inhibiting proliferation of melanoma cell lines.
Pharmacological inhibition of C-P4H has anti-proliferative effects on melanoma cells irrespective of P4HA3 status and results in dosedependent G2-M cell cycle block. Detection of methylated P4HA3 in genomic DNA from the peripheral blood of melanoma patients is a sensitive and specific biomarker of metastatic melanoma. Conclusions: Our data thus identify the C-P4H family as potentially important modulators of melanoma growth and imply that pharmacological inhibitors of collagen prolyl 4-hydroxylation merit further investigation as novel anti-melanoma therapeutics. Further, the frequent methylation of P4HA3 in metastatic melanoma suggests that P4HA3 may have utility as a tissue and serum biomarker of metastatic disease. Background: Melanoma has a high metastatic potential due to its tendency to metastasize through blood and lymphatic vessels. However, to date, effective treatments for metastatic melanoma are lacking and the prognosis of these patients remains very poor. One major goal of melanoma research is to identify new molecular targets for the development of novel treatments aimed to counteract intra and/ or extravasation of melanoma cells. Several studies support the role of the urokinase-type plasminogen activator receptor (uPAR) in melanoma as increased expression of uPAR has been found to be associated with poor prognosis and increased risk of metastasis [1,2]. uPAR forms complex signaling units with trans-membrane receptors, including G protein coupled Formyl Peptide Receptors (FPR)s [3]. These complexes lead to the activation of signaling cascades controlling cell migration as well as growth and survival. The uPAR 84-95 chemotactic sequence is required to induce cell motility by interacting with FPRs that, in turn, signal through the integrins [4,5]. By a drug-design approach based on the conformational analysis of the uPAR chemotactic sequence, we have developed a family of peptides which inhibit cell migration by preventing uPAR/FPR-1 interaction [6,7,8]. This study was aimed to investigate the contribution of uPAR on the capability of melanoma cells to cross endothelial barriers during metastasis with the aim to block this process. Materials and methods: Human melanoma A375 and M14 cell lines expressing different levels of uPAR and comparable levels of FPR-1 on cell surface, were analyzed for their ability to move toward chemotactic gradients, to invade extra-cellular matrix and to disrupt endothelial monolayers using the Real Time Cell Analysis System and the xCELLigence technology [9]. Results: We found that uPAR levels positively correlate with motility, invasiveness and capability of human melanoma cells to cross endothelial monolayers. The important role of the uPAR 84-95 sequence in determining invasive ability of melanoma cells was confirmed by the finding that specific antibodies recognizing uPAR 84-95 as well as peptide inhibitors of the uPAR 84-95 /FPR1 interaction abrogate melanoma cell ability to move toward chemotactic gradients, to invade basal membranes and to cross endothelial monolayers. Conclusions: These findings identify uPAR as a novel prognostic marker, the FPR as novel therapeutic target in melanoma and suggest that inhibitors of the uPAR 84-95 /FPR1 interaction may be useful for the treatment of metastatic melanoma. Background: Exosomes (Exo) are nanovesicles produced by tumor cells that regulate the intercellular signals leading to cell proliferation and spreading to distant sites [1]. Variable amounts of Exo produced within the tumor microenvironment by both malignant and accessory cells also participate to enhance both migration and invasiveness [2] and recent studies support the role of Exo in tumor progression of several cancer models [3,4]. However, their effect in melanoma progression has not been completely elucidated [5] and we explored here their chemotactic activity in vitro. Materials and methods: Exo were purified by ultracentrifugation from culture medium of primary (LCP) and metastatic (LCM) melanoma cell lines. The ability of LCP and LCM to migrate was explored either in presence of Exo stimulation or not, using 8 μm trans-well chambers. Briefly, the upper chambers were filled with 10 4 cells in 1 % fetal bovin serum (FBS) Exo-free medium, whereas the lower chambers were filled with the same medium supplemented with LCP-or LCM-Exo at different concentrations (10-50 μg/ml). Cells entrapped within the membrane were visualized after nuclei counterstaining with DAPI and counted at 40× magnification in at least five microscopic fields. Mann-Whitney test was used for statistical analyses. Results: Not-stimulated LCP and LCM showed a similar migratory behaviour (13.5 ± 2.3 and 16.3 ± 2.6 cells/field, respectively) that, however, was significantly increased by stimulation with homologous Exo. In particular, LCP-and LCM-Exo stimulation at 10 μg/ml produced a 2.3-and 2.7-fold-increase of the migratory capacity as compared to the corresponding untreated cells (p = 0.01) and this effect was apparently J Transl Med 2016, 14(Suppl 1):S65 dependent on Exo concentration (p < 0.05). Furthermore, the stimulation by Exo derived from the metastatic LCM cell line provoked an increased number of migrated LCP cells with respect to both untreated cells (4.47, 5.52 and 7.96-fold increase at 10, 20 and 50 μg/ml, respectively) and LCP-Exo stimulated cells (1.96, 2.19 and 2.28-fold increase, respectively) (p < 0.0002). Conclusion: Although preliminary, our data appear to support the hypothesis that Exo released by melanoma cells enhance the chemotactic activity of primary tumor cells and that this effect is mainly evident when using line-related or homologous Exo. Therefore, it is suggestive that they may have a role in tumor progression in melanoma in particular in favoring a metastatic phenotype.

P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma
Background: Metabolic reprogramming is a peculiarity of tumoral cells. Its role in melanoma has been described but molecular actors, the influence of BRAF mutations on cell metabolism and molecules involved in bioenergetic transformation, have not been clearly defined. Materials and methods: Energetic metabolism of melanoma cell lines with different BRAF mutational status ( Table 2) was studied through the evaluation of oxygen consuption, ATP, lactate and ROS levels. Western blot analysis of subunits of mitochondrial respiratory chain (17 kDa, Cox IV), porin (marker for mitochondrial matrix), lactate carriers (MCT1, MCT4) and MITF were also performed. Furthermore, mRNA levels of regulators of mitochondrial biogenesis (PGC-1alpha, PGC-1beta), their targets (TFAM, cyt c) and HIF-1alpha were evaluated. Results: BRAFV600 cell lines showed lower levels of MITF, PGC-1alpha/ PGC-1beta and a downregulation of oxidative metabolism related to a low oxygen consumption and to a higher glycolytic ATP production, compared to BRAFwt cell lines. These latter showed an increased expression of HIF-1alpha (50-200 %), MCT4 (150 %) and extracellular lactate (about 20 %).

Conclusions:
Our results highlight the existence of a specific metabolic phenotype related to BRAF mutational status. These data demonstrated the possibility to take into account drugs acting on cellular metabolism for the treatment of metastatic melanoma, in order to support the activity of anti BRAF/antiMEK drugs or to overcome resistance mechanism. Background: Immunotherapy is presently providing favourable clinical responses in metastatic melanoma (MM) and appears as innovative approach to be applied to other solid tumors. However, the therapeutic response is temporary and additional therapeutic approaches may extend its effectiveness and duration. Lenalidomide (Len) is an immunomodulant drug (IMiD) showing anti-inflammatory and antitumor properties in several hematologic disorders [1], as well as antimelanoma activity in phase 2/3 clinical trials in MM [2]. Furthermore, in association with Sorafenib Len exerts a defined anti-angiogenic effect in a human ocular melanoma xenograft model [3]. As IMiD, Len activates the CD28 checkpoint expressed by T cells and drives the NF-kB activation downstream the p21 cell cycle negative regulator, while increasing the T-cell cytotoxicity. This activity occurs by overcoming the inhibition of CTLA4 [4]. Therefore, this study explores the molecular activity of Len against melanoma cells for future translation to clinical treatment of melanoma. Materials and methods: Three melanoma cell lines (A375, SKMEL28, WN266) were first cultured in serum-free medium to synchronize the cell cycle and then for 24 h in complete medium, supplemented with Len at different concentrations from 0.01 to 100 μM. A standard curve of cytotoxicity was assessed to measure the IC 50 whereas both viability and proliferation of melanoma cells were evaluated by MTT assay. The effect of Len on the cycle phases was investigated by measuring the DNA content by flow-cytometry after cell staining with propidium iodide. Finally, real-time PCR explored the RNA expression levels of p21. Results: All three melanoma cell lines showed a threefold decrease of their proliferation extent by Len at 10 μM (mean values: 640 ± 30 OD vs 1.915 ± 15 OD, p < 0.05). However, the majority of cells were viable (>91 %) although frozen at the G0-G1 phase of cell-cycle (64 ± 10 %) with respect to untreated cells (38 ± 4.6 %). Percentage number of apoptotic cells was apparently similar (Len-treated: 0.7 ± 0.02 vs untreated: 1.7 ± 0.04 %) as well as those undergoing to S and G2-M phases (Len-treated: 35 ± 3 vs untreated: 60 ± 2 %). After treatment with Len, melanoma cell were up-regulated in their p21 RNA content (p < 0.01).

Conclusions:
Len exerts a cytostatic effect on melanoma cell lines through p21 up-regulation that restrains the NFkB activity. This provides the rationale for planning further pre-clinical investigations exploring the Len effect on both CDK4 and CDK6 expression and activity, in order to design combination strategies with negative regulators of the cell cycle for the treatment of melanoma. Background: Harnessing the T-cell response has proven to be a successful strategy in the prevention of tumor relapse. Recently we reported that Melan-A-specific CD8 T cells isolated from long-term surviving patients treated with DTIC before peptide-vaccination plus IFN-α possess higher anti-tumor reactivity and an enlarged T-cell repertoire, compared to cells isolated after vaccination alone, suggesting that chemoimmunotherapy may favor a protective anti-tumor specific immune response.

Materials and methods:
To identify the mechanisms enhancing the immune response, we analyzed the endogenous and treatmentinduced antigen specific CD8+ T-cell response in a panel of Melan-A-and gp100-specific clones from five patients. We analyzed the differentiation phenotype (CCR7 and CD45RA), the co-stimulatory (CD27, CD28 and ICOS) and inhibitory (TIM-3, LAG-3 and PD-1) profile, in parallel with the polyfunctionality (IFN-γ, TNF-α and Granzyme B) and activation of AKT (pSer473-AKT). Results: Melan-A-specific T cells isolated from the endogenous response of both treatments showed poor polyfunctionality and low ICOS expression and an AKT activation status related to the differentiation profile (in term of CD28 and/or CD27 expression). Conversely, after therapy only patients treated with combined chemoimmunotherapy showed tumor-specific CD8+ T cells displaying the hallmarks of differentiated and highly activated effector T cells. These clones were highly efficient in tumor killing, possessed polyfunctional activity, up-regulated inhibitory receptors, retained proliferative capability and activated an AKT pathway not-related to the differentiation phenotype and dependent on ICOS engagement. Strikingly, T-cell polyfunctionality elicited by the combined therapy was strictly dependent on this AKT activation, as demonstrated by the blockade with selective inhibitors, which occurred only in Melan-A-specific CD8+ T cells and not in cells specific for gp100, suggesting that the nature of the peptide is crucial for the activation of this pathway.

Conclusions:
We suggest that the phenotypic and functional T-cell signature elicited by chemoimmunotherapy is a fine-tuned balance between quality of the Ag/TCR complex, co-stimulatory signals such as ICOS, inhibitory checkpoints and AKT activation, associated with anti-tumor T cells that can protect patients from tumor recurrence. The study represents a critical contribution for the comprehension of the mechanisms underlying the advantages of combined chemo-immunotherapy and paves the way for the identification of new biomarkers of T-cell activation that may be employed as markers of immune responsiveness. Results: Among our patients no malignant and hyperproliferative skin lesions, interstitial lung disease, venous thromboembolism, gastrointestinal bleeding and heart (cardiomyopathy, decreased left ventricular ejection fraction) toxicities were appreciated. Evolution of melanocytic nevi was also assessed, none of the monitored nevi increased in pigmentation nor morphological changes in preexisting nevi was seen following combination therapy. The most common adverse events (G1 grade) were fatigue (25 %) and pyrexia (23 %), no treatment discontinuation was necessary. Cutaneous rash (G1) occurred in 11 %, diarrhea (G1) and arthralgia (G1) in 5 %, ocular uveitis occurred in 2 % of 54 patients, but no dose modifications were necessary. Severe papilloedema occurred in 1 patient of 54, that led to permanent therapy discontinuation. Clinically meaningful improvements from baseline in favour of dabrafenib/trametinib were observed for pain, nausea and vomiting, distress and appetite at weeks 8 already. . Therapy with dexamethasone 4 mg IM every 6 h was started; due to the low decreasing THS values, levothyroxine 100 mcg once daily was also added. A rapid symptoms improvement was obtained by this therapeutic approach. The dose of dexamethasone was gradually decreased over 4 weeks and hydrocortisone replacement of 20 mg in twice daily doses has been just started. The fourth course of Ipilimumab was not performed because of the contemporary high-dose glucocorticoid therapy; furthermore, it occurred delayed liver toxicity: AST 160 U/L (15-46) and ALT 350 U/L (11-66). Total body CT-scan and brain MRI were scheduled, but a significant shrinkage in axillary lymph node swelling by clinical examination was observed. Discussion: Development of IH is associated with a significant clinical morbidity, so early recognition and therapeutic intervention are extremely relevant. Furthermore, in the absence of data demonstrating clinical benefit from high-dose glucocorticoid therapy, we wondered if, in absence of symptoms such as visual disturbances, there is the indication to start with hydrocortisone replacement therapy alone from the beginning [1]. We also wondered if it was reasonable to administer Ipilimumab during prolonged high-dose glucocorticoid therapy. Thus, guidelines for surveillance and management of IH are highly required [9,10].

P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients
Consent to publish Written informed consent for publication of their clinical details was obtained from the patient/parent/guardian of the patient. A copy of the consent form is available for review by the Editor of this journal. Background: For specific subsets of melanocytic proliferations, there are morphologic limitations in the histologic diagnosis, especially for borderline melanocytic tumors. [1]. In particular, Spitzoid proliferations can be difficult to diagnose. For these reasons, in the last years, clinic research has focused attention on discovery of new diagnostic markers.

Tumor microenvironment and biomarkers
Published gene expression and proteomic profiling data indicate new candidate molecules involved in melanoma pathogenesis, and useful in differential diagnosis of difficult melanocytic lesions [2,3]. Recently, the diagnostic power of galectin-3 was demonstrated in a series of melanocytic lesions, with a strong increasing of expression in malignant lesions compared with benign lesions. Similarly, the accumulation of Collagen XVII antibody was detected in vertical melanoma fronts and associated with invasive phenotype. Moreover, overexpression of cyclin D1 and p21 was detected in Spitz nevi compared with non-spitzoid melanomas, Ki-67 appears highly expressed in deep areas of non-spitzoid melanomas [4,5] The purpose of this study was to evaluate the expression of a panel of markers, suggested by literature, on a series of melanocytic lesions selected from our archives, to define the most useful for the differential diagnosis. Materials and methods: We selected 56 samples from database of Pathology Unit of I.N.T. "G. Pascale" (Naples): 24 atypical Spitz tumor, 10 atypical Spitz nevi, 12 primary melanomas, 5 blue nevi and 5 common nevi. The samples were analyzed by immunohistochemistry for the expression of Cyclin D1, Ki67, Galectin 3, COX2, Topoisomerase 2α, Collagen XVII, GLUT1, Survivin. Ten atypical lesions and ten melanomas were also used for a molecular analysis to evaluate specific chromosomal aberrations, typical of melanoma, by FISH. Results: Almost all of the atypical lesions showed a low proliferative index (<5 %), while the high expression of Ki67 is present in malignant lesions. The expression of cyclin D1, collagen XVII and Topoisomerase 2α was high in borderline lesions and in melanomas with a Breslow thickness >1 mm and high mitotic index, and lower in common and blue nevi. The expression of COX2, survivin is not particularly significant, reflecting the trend described in the literature. Only three atypical lesions showed alteration in the RREB1 locus. Conclusions: Our preliminary data showed that Cyclin D1, the collagen XVII and Topoisomerase 2α could provide useful diagnostic and prognostic markers for atypical lesions, being significantly overexpressed in invasive lesions. Conclusion: Simultaneous measurement of LDH, CRP and MIA identifies a larger number of patients than measurement of any marker alone or any possible combination of two of them. But adding LDH to MIA/CRP association leads to an increase in sensitivity with only 4 %. Although serum LDH is used in TNM staging system, we noted that, even in stage IV, it has a lower sensitivity than either of the other two studied markers. Regarding stage IV patients, MIA/CRP combination has 100 % sensitivity, making LDH determination useless. We believe that simultaneous measurement of MIA/CRP best describes melanoma patients. Conclusions: These data allowed us to speculate on the fundamental role played by HOTAIR in the tumor evolution of melanoma. In addition, its presence in intratumoral lymphocytes could suggest that it may be also involved in the modulation of the tumor microenvironment [5]. Finally, its detection in serum might suggests its use, as circulating serum marker, in the management of melanoma patients. J Transl Med 2016, 14(Suppl 1):S65

Source of funding
with depressive symptoms (r = −0.484), and transcendent orientation positively correlates with depressive symptoms (r = 0.337). Conclusions: Melanoma and psychopathological aspects correlate positively with each other, especially in relation to gender, marital status, education, risk factors and coping styles.
In cancers with increasing aggressiveness, cancer cells specialize for enhanced proliferation and cell survival. Simultaneously, they specialize on exploiting the host for supporting tumor growth. Consequently, many of the host's reactions are contributing to the malignant behaviors of cancers. In turn, the immune system has a number of capabilities that have the potential of counteracting tumor growth and protecting the patient. Specifically, CD8+ cytotoxic T cells and CD4+ T helper one cells can destroy up to large tumor masses. More importantly, these anti-cancer T cells can provide long-term protection by keeping (minimal) residual disease in check, and patients alive for many years. However, in most patients T cells are dysfunctional and remain in a state of T cell "exhaustion". Novel antibody therapies that block inhibitory receptors can lead to strong activation of antitumor T cells, mediating clinically significant anti-cancer immunity for many years. Therapeutic interventions are now being optimized for enforcing anti-cancer T cell functions, and avoiding immune inhibitory mechanisms of malignant diseases. Novel therapy modalities will likely become beneficial, provided that they help tipping the balance towards more activation and less inhibition of anti-cancer T cells. Carefully designed clinical studies with state-of-the art therapeutic and analytical techniques will provide detailed insight in the tumor microenvironment of patients, and the underlying mechanisms that cause tumor growth or regression. Such information is crucial for the design of promising large-scale (combination therapy) trials. Lung cancer is the leading cause of cancer-related deaths in men and the second leading cause in women world-wide 1 . Approximately 85 % of lung cancers are non-small cell lung cancers 2, 3 and about 30 % of these, have a squamous histology which is associated with poorer outcomes and limited treatment options 4 . The human immune system can be an effective way of fighting cancer. One mechanism the lymphatic checkpoint uses, to negatively regulate the early stages of T-cell activation, is through expression of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and antibody blockade of CTLA-4 has been shown to increase antitumor immunity 5 .

Immunotherapy in oncology
In peripheral tissues, the effector phase of the adaptive immune response against tumor cells is partly negatively regulated through the binding of the programmed cell death protein 1 (PD-1) expressed on activated T-cells with the ligands PD-L1 or PD-L2 expressed on tumor cells. Tumor cells can evade the immune response through the upregulation of PD-L1 in tumors or the tumor microenvironment 6 , leading to immune resistance. CTLA-4 inhibitors re-activate T-cells by blocking the deactivating effects of CTLA-4. PD-1 and PD-L1 inhibitors re-activate T-cell activity in peripheral tissues by blocking the binding of PD-1 to its ligand PD-L1. Two CTLA-4 inhibitors, two PD-1 inhibitors, and four PD-L1 inhibitors are under development for NSCLC 7 . Nivolumab recently received FDA approval for use as a single agent in second-line squamous NSCLC based on phase III trial data [8,9]. The presentation will review available evidence for use of checkpoint inhibitors in advanced NSCLC.